162 related articles for article (PubMed ID: 34887513)
1. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
Aslam S; Ameer S; Shabana NA; Ahmed M
Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
4. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
Wu S; Wang M; Alqahtani A; Lou M; Stock W; Bhojwani D; Alachkar H
Biomed Pharmacother; 2022 Jun; 150():113000. PubMed ID: 35658244
[TBL] [Abstract][Full Text] [Related]
5. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Alachkar H; Fulton N; Sanford B; Malnassy G; Mutonga M; Larson RA; Bloomfield CD; Marcucci G; Nakamura Y; Stock W
Pharmacogenomics J; 2017 Jun; 17(3):274-279. PubMed ID: 27019981
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Abaji R; Gagné V; Xu CJ; Spinella JF; Ceppi F; Laverdière C; Leclerc JM; Sallan SE; Neuberg D; Kutok JL; Silverman LB; Sinnett D; Krajinovic M
Oncotarget; 2017 Jul; 8(27):43752-43767. PubMed ID: 28574850
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
9. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
[TBL] [Abstract][Full Text] [Related]
10. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.
Liu SG; Li ZG; Cui L; Gao C; Li WJ; Zhao XX
Leuk Lymphoma; 2011 Jun; 52(6):1030-40. PubMed ID: 21534867
[TBL] [Abstract][Full Text] [Related]
11. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
13. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia.
Zawitkowska J; Lejman M; Zaucha-Prażmo A; Drabko K; Płonowski M; Bulsa J; Romiszewski M; Mizia-Malarz A; Kołtan A; Derwich K; Karolczyk G; Ociepa T; Ćwiklińska M; Trelińska J; Owoc-Lempach J; Niedźwiecki M; Kiermasz A; Kowalczyk J
In Vivo; 2019; 33(4):1333-1339. PubMed ID: 31280227
[TBL] [Abstract][Full Text] [Related]
14. Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
Tantawy AAG; Ebeid FSE; Adly AAM; El-Ghoroury E; Mostafa M
J Genet; 2017 Dec; 96(6):905-910. PubMed ID: 29321348
[TBL] [Abstract][Full Text] [Related]
15. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Liu Y; Fernandez CA; Smith C; Yang W; Cheng C; Panetta JC; Kornegay N; Liu C; Ramsey LB; Karol SE; Janke LJ; Larsen EC; Winick N; Carroll WL; Loh ML; Raetz EA; Hunger SP; Devidas M; Yang JJ; Mullighan CG; Zhang J; Evans WE; Jeha S; Pui CH; Relling MV
Clin Pharmacol Ther; 2017 Jul; 102(1):131-140. PubMed ID: 28090653
[TBL] [Abstract][Full Text] [Related]
17. Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
J Pediatr Hematol Oncol; 2017 Nov; 39(8):589-595. PubMed ID: 28719513
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
Rocha JC; Cheng C; Liu W; Kishi S; Das S; Cook EH; Sandlund JT; Rubnitz J; Ribeiro R; Campana D; Pui CH; Evans WE; Relling MV
Blood; 2005 Jun; 105(12):4752-8. PubMed ID: 15713801
[TBL] [Abstract][Full Text] [Related]
19. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.
Suzuki H; Fukushima H; Suzuki R; Hosaka S; Yamaki Y; Kobayashi C; Sakai A; Imagawa K; Iwabuchi A; Yoshimi A; Nakao T; Kato K; Tsuchida M; Kiyokawa N; Koike K; Noguchi E; Fukushima T; Sumazaki R
J Hum Genet; 2016 Sep; 61(9):797-801. PubMed ID: 27193222
[TBL] [Abstract][Full Text] [Related]
20. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
